Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo Nordisk predicted growth will slow this year. The Danish pharmaceutical company has ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...

Novo Nordisk reported soaring sales for weight loss drug Wegovy (James Manning/PA) Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo ...

Obesity drug maker Novo Nordisk NVO-N forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as “good ...

Share on Pinterest LeoPatrizi/Getty Images Semaglutide is the active ingredient in Wegovy, Ozempic, and Rybelsus. Currently, only Wegovy is approved for weight loss in the United States.

One jab, Wegovy, is already available to some people and a second, Mounjaro, will soon be available - although it could be more than a decade before it is fully rolled-out. NHS experts have warned ...

Demand for weight loss jabs continues to surge and has been spurred on by the NHS offering Wegovy to patients and will start offering Mounjaro in March 2025. They have also become increasingly popular ...

It was dubbed the "King Kong" of weight loss drugs by US expert Dr Julio Rosenstock after its effect size emerged , compared to the "gorilla" of Wegovy. The two biggest selling GLP-1 drugs are ...